Otsuka Pharmaceutical to Acquire Astex

Japan’s Otsuka has agreed to purchase cancer specialist, Astex Pharmaceuticals, in a deal which is valued at $886 million. Otsuka will obtain the remaining shares of Astex for $8.50 per share in cash, signifying a 48% premium to the average closing stock price for the prior 30-day period. One of the main reasons behind the

Continue Reading